MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer
Yamamoto, K.; Ueno, T.; Kawaoka, T.; Hazama, S.; Fukui, M.; Suehiro, Y.; Hamanaka, Y.; Ikematsu, Y.; Imai, K.; Oka, M.; Hinoda, Y.
Anticancer Research 25(5): 3575-3579
2005
ISSN/ISBN: 0250-7005 PMID: 16101182 Document Number: 593435
Background: To evaluate the immunogenicity of MUC1 peptide vaccine in advanced pancreatic and bile duct cancers, a phase I clinical trial was conducted. Materials and Methods: A 100-mer MUC1 peptide consisting of the extracellular tandem repeat domain and incomplete Freund's adjuvant were subcutaneously administered to 6 pancreatic and 3 bile duct cancer patients at weeks 7, 3 and 5 and doses ranging from 300 to 3000 mu g. Circulating intracytoplasmic cytokine-positive CD4(+) T cells and anti-MUC1 IgG antibodies were measured before and after vaccination. Results: There were no adverse events, except for mild reddening and swelling at the vaccination site. In 8 patients eligible for clinical evaluation, 7 had progressive disease and I stable disease with a tendency for increased circulating anti-MUC1 IgG antibody after vaccination. Conclusion: This phase I clinical trial revealed the safety of a vaccine containing 100-mer MUC1 peptides and incomplete Freund's adjuvant.